NVAX Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 82.81% compared to Novavax's net margin of 21.68%. Novavax's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Novavax has a consensus price target of $13.43, signalling upside risk potential of 92.94%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Novavax has higher upside potential than Eli Lilly and, analysts believe Novavax is more attractive than Eli Lilly and.

Novavax has a beta of 2.691, which suggesting that the stock is 169.079% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Novavax pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novavax quarterly revenues are $626.3M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Novavax's net income of $518.6M is lower than Eli Lilly and's net income of $2.8B. Notably, Novavax's price-to-earnings ratio is 2.63x while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 0.95x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 82.81% compared to Novavax's net margin of 32.71%. Novavax's return on equity of -- beat Merck &'s return on equity of 39.02%.

Novavax has a consensus price target of $13.43, signalling upside risk potential of 92.94%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 23.48%. Given that Novavax has higher upside potential than Merck &, analysts believe Novavax is more attractive than Merck &.

Novavax has a beta of 2.691, which suggesting that the stock is 169.079% more volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.88% to investors and pays a quarterly dividend of $0.81 per share. Novavax pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novavax quarterly revenues are $626.3M, which are smaller than Merck & quarterly revenues of $15.5B. Novavax's net income of $518.6M is lower than Merck &'s net income of $5.1B. Notably, Novavax's price-to-earnings ratio is 2.63x while Merck &'s PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 0.95x versus 3.27x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 82.81% compared to Novavax's net margin of -907.48%. Novavax's return on equity of -- beat Moderna's return on equity of -29.23%.

Novavax has a consensus price target of $13.43, signalling upside risk potential of 92.94%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Novavax has higher upside potential than Moderna, analysts believe Novavax is more attractive than Moderna.

Novavax has a beta of 2.691, which suggesting that the stock is 169.079% more volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Novavax quarterly revenues are $626.3M, which are larger than Moderna quarterly revenues of $107M. Novavax's net income of $518.6M is higher than Moderna's net income of -$971M. Notably, Novavax's price-to-earnings ratio is 2.63x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 0.95x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 82.81% compared to Novavax's net margin of 21.63%. Novavax's return on equity of -- beat Pfizer's return on equity of 8.72%.

Novavax has a consensus price target of $13.43, signalling upside risk potential of 92.94%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Novavax has higher upside potential than Pfizer, analysts believe Novavax is more attractive than Pfizer.

Novavax has a beta of 2.691, which suggesting that the stock is 169.079% more volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Novavax pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Novavax quarterly revenues are $626.3M, which are smaller than Pfizer quarterly revenues of $13.7B. Novavax's net income of $518.6M is lower than Pfizer's net income of $3B. Notably, Novavax's price-to-earnings ratio is 2.63x while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 0.95x versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.